Studies using patient cohorts prior to the advent of both routine BRAF genotyping and BRAFi correlated increased nuclear or cytoplasmic β-catenin with improved survival [22]–[24], so this current result raises the question as to whether patients with BRAF-mutant melanomas exhibiting high levels of nuclear β-catenin could potentially do better with other therapies or combinations of targeted drugs. The gene discussed is BRAF; the disease is melanoma.